Table 3.
The mean diameter (z-average), PDI, and zeta potential of the various formulations
| Formulation | z-average size(nm)± SD | PDI ±SD | zeta potential (mV)±SD |
|---|---|---|---|
| SLN-pp | 132.4±2.1 | 0.220±0.02 | -25.5±0.6 |
| SLN-pp MAG | 130.6±2.8 | 0.223±0.02 | -18.1±0.9 |
| NLC-pp | 113.8±3.3 | 0.162±0.00 | -15.9±2.1 |
| NLC-pp MAG | 101.1±2.1 | 0.111±0.02 | -18.3±1.3 |
| SLN-cp | 161.2±2.3 | 0.256±0.00 | -28.3±0.9 |
| SLN-cp MAG | 152.9±2.8 | 0.244±0.01 | -29.3±1.3 |
| NLC-cp | 159.4±1.9 | 0.268±0.02 | -19.6±1.1 |
| NLC-cp MAG | 153.5±2.3 | 0.133±0.01 | -29.2±0.9 |
| SLN-tt | 186.0±0.5 | 0.177±0.01 | -17.3±2.1 |
| SLN-tt MAG | 147.1±0.2 | 0.141±0.01 | -24.4±1.2 |
| NLC-tt | 106.9±1.3 | 0.121±0.02 | -24.3±2.0 |
| NLC-tt MAG | 101.0±1.8 | 0.114±0.00 | -28.2±1.1 |
Pp : Precirol®, Poloxamer with deionized water; pp MAG :Precirol®, Poloxamer with magnetized water; cp: Compritol®, Poloxamer with deionized water; cp MAG: Compritol®, Poloxamer with magnetized water; tt: Tripalmitin,Tween 80 with deionized water; tt MAG: Tripalmitin,Tween 80 with magnetized water